Death · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Intervention not reported
PFS: relapse or death · individuals with HL
The intervention probably leads to higher PFS: relapse or death (moderate certainty).
1 finding from 1 review
Treatment‐related death · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in treatment‐related death compared with no bortezomib (low certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention showed no clear difference in death on induction therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention showed no clear difference in death on induction therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention probably leads to higher death on induction therapy (moderate certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).
1 finding from 1 review
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Relapses/death (instead of PFS) · Participants with PCNSL
The intervention may leads to lower relapses/death (instead of PFS) (low certainty).
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy not reported · patients with newly diagnosed AML
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported